- Home
- APCX vs RLMD Comparison
APCX vs RLMD Comparison
Compare APCX & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APCX
- RLMD
- Stock Information
- Founded
- APCX 2006
- RLMD 2004
- Country
- APCX United States
- RLMD United States
- Employees
- APCX N/A
- RLMD N/A
- Industry
- APCX Finance: Consumer Services
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- APCX Finance
- RLMD Health Care
- Exchange
- APCX Nasdaq
- RLMD Nasdaq
- Market Cap
- APCX 11.7M
- RLMD 11.5M
- IPO Year
- APCX N/A
- RLMD N/A
- Fundamental
- Price
- APCX $0.38
- RLMD $0.28
- Analyst Decision
- APCX
- RLMD Hold
- Analyst Count
- APCX 0
- RLMD 4
- Target Price
- APCX N/A
- RLMD $4.25
- AVG Volume (30 Days)
- APCX 78.1K
- RLMD 381.8K
- Earning Date
- APCX 05-13-2025
- RLMD 03-27-2025
- Dividend Yield
- APCX N/A
- RLMD N/A
- EPS Growth
- APCX N/A
- RLMD N/A
- EPS
- APCX N/A
- RLMD N/A
- Revenue
- APCX $276,000.00
- RLMD N/A
- Revenue This Year
- APCX $1,315.48
- RLMD N/A
- Revenue Next Year
- APCX N/A
- RLMD N/A
- P/E Ratio
- APCX N/A
- RLMD N/A
- Revenue Growth
- APCX N/A
- RLMD N/A
- 52 Week Low
- APCX $0.31
- RLMD $0.24
- 52 Week High
- APCX $1.49
- RLMD $5.09
- Technical
- Relative Strength Index (RSI)
- APCX 47.55
- RLMD 40.39
- Support Level
- APCX $0.37
- RLMD $0.26
- Resistance Level
- APCX $0.45
- RLMD $0.33
- Average True Range (ATR)
- APCX 0.02
- RLMD 0.03
- MACD
- APCX 0.00
- RLMD 0.00
- Stochastic Oscillator
- APCX 45.52
- RLMD 10.76
About APCX AppTech Payments Corp.
AppTech Payments Corp is a FinTech company utilizing various payment processing and digital banking technologies to complement core merchant services capabilities. The company's patented and proprietary software will provide progressive and adaptable products that are available through a suite of synergistic offerings directly to merchants, banking institutions, and business enterprises. It is developing a secure digital payments and banking platform that powers commerce experiences for clients and customers. Based upon industry standards for payment and banking protocols, the company will offer standalone products and fully integrated solutions that deliver unparalleled payments, banking, and financial services experiences.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.